29 June 2026
Policy briefs launched by National Cancer Society Malaysia and Boehringer Ingelheim highlights significant rates of co-existing cardiovascular, kidney, and metabolic diseases among Malaysians.
Tag: heart disease
12 June 2026
HRPB's cardiology service is undergoing a temporary "drastic restructuring" amid staff shortages, including one-year appointments for all referrals to the cardiology clinic, except pregnant patients. The restructuring affects both inpatient and outpatient.
30 January 2026
APHM says while the Base MHIT Plan's RM100k coverage is likely adequate for "relatively straightforward" procedures like appendectomy, it probably won't be sufficient for advanced surgery like CABG. Ischaemic heart disease is Malaysia's top cause of death.
17 September 2025
Retinal scans, aided by artificial intelligence, may soon offer doctors a simple, non-invasive way to detect several medical conditions.
22 August 2025
Make Samsung's Galaxy Watch8 your personal health coach, the world's first smartwatch that measures your antioxidant level. The Galaxy Watch8 has complete heart monitoring, measuring your vascular load, BP and heart rate, besides tailored workout routines.
26 February 2025
Malaysia
Maaedicare Charitable Foundation Introduces Legacy Giving: A Gift Beyond Time For Kidney And Heart Patients Across Generations
Maaedicare Charitable Foundation recently introduced its Legacy Giving Program, calling on donors to leave a legacy of compassion and sustain life-saving health care services.
2 December 2024
2024 is the Year of the Payer in Malaysian health care, with three major policy decisions that benefited payers for health care: health insurance copay mandate, IJN's mandated shift to generics, and the staggered rollout of doctors' on-call allowance hike.
5 November 2024
The Pharmaceutical Association of Malaysia tells the government that just changing medicines for IJN, from originator to generics, won't solve cost management problems. "It may even backfire" with a higher disease and cost burden if patients deteriorate.
1 November 2024
MMA calls for patient education and obtaining the best quality generic medicines, after the government directed IJN to switch its public patients to generics. In cases where generic versions aren't available, MMA says originator drugs must still be given.
21 October 2024
MOH paid IJN Sdn Bhd RM606.5 million in 2023 for some 234,000 visits from 48,000 government-dependent patients. If MOF Inc approves IJN's fee hike of 10-40%, with pensioners set to stay at IJN, MOH may possibly pay RM660 million to RM840 million in 2025.